Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential
- 4 December 2020
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 16 (6) , 1034-1046
Abstract
Signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are two closely related STAT family members that are crucial downstream effectors of tyrosine kinase oncoproteins such as FLT3‐ITD in acute myeloid leukemia (AML) and BCR‐ABL in chronic myeloid leukemia (CML). We recently developed and reported the synthesis of a first molecule called 17 f that selectively inhibits STAT5 signaling in myeloid leukemia cells and overcomes their resistance to chemotherapeutic agents. To improve the antileukemic effect of 17 f, we synthesized ten analogs of this molecule and analyzed their impact on cell growth, survival, chemoresistance and STAT5 signaling. Two compounds, 7 a and 7 a’, were identified as having similar or higher antileukemic effects in various AML and CML cell lines. Both molecules were found to be more effective than 17 f at inhibiting STAT5 activity/expression and suppressing the chemoresistance of CML.Keywords
This publication has 43 references indexed in Scilit:
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsGenes & Cancer, 2012
- Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia ActivityJournal of Medicinal Chemistry, 2012
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsBlood, 2011
- Stat5 is indispensable for the maintenance of bcr/abl‐positive leukaemiaEMBO Molecular Medicine, 2010
- STAT5 signaling in normal and pathologic hematopoiesisFrontiers in Bioscience-Landmark, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5bToxicology and Applied Pharmacology, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Cytogenetic and molecular mechanisms of resistance to imatinibSeminars in Hematology, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001